← Back to headlines
Radiopharm Schedules FDA Meeting for Brain Imaging Agent RAD101
Radiopharm has scheduled a meeting with the FDA regarding its brain imaging agent, RAD101.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Otedola Increases First HoldCo Stake with N20.7 Billion Share Purchase
52m ago
Alphabet Launches Inaugural Australian Dollar Bond Sale for AI Investment
2h ago
Paramount Seeks $1.88 Billion Bond in Merger Lawsuit
2h ago
German government open to selling Commerzbank stake to UniCredit under conditions
2h ago